Related Experiment Video

Updated: Jun 6, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K

Nanaomycin K Inhibited Cell Proliferation and Epithelial-Mesenchymal Transition in Renal Cell Carcinoma

Aya Hiraoka1, Yuto Hirata1, Yuki Kan1

  • 1Department of Public Health, Kobe University Graduate School of Health Sciences.

Biological & Pharmaceutical Bulletin
|December 1, 2024
PubMed

Insights

Nanaomycin K, a natural compound, effectively inhibits renal cell carcinoma (RCC) growth and migration by blocking epithelial-mesenchymal transition (EMT). This compound shows promise as a potential therapeutic agent for advanced RCC.

Area of Science:

  • Natural Products Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Epithelial-mesenchymal transition (EMT) is a key mechanism in cancer cell migration and metastasis.
  • Renal cell carcinoma (RCC) is a significant cause of cancer-related mortality.
  • Identifying novel therapeutic agents targeting EMT is crucial for improving RCC treatment outcomes.

Purpose of the Study:

  • To investigate the EMT-inhibitory and antitumor effects of Nanaomycin K in renal cell carcinoma (RCC).
  • To evaluate Nanaomycin K's efficacy in preclinical models of RCC.

Main Methods:

  • In vitro studies using RCC cell lines (ACHN, Caki-1, Renca) treated with Nanaomycin K.
  • Assessment of cell proliferation, apoptosis, and migration (wound healing assays).
  • In vivo studies involving tumor-bearing mice treated with Nanaomycin K.

Main Results:

  • Nanaomycin K significantly inhibited RCC cell growth, migration, and induced apoptosis, particularly in the presence of transforming growth factor (TGF)-β.
  • Gene expression analysis revealed Nanaomycin K's modulation of EMT markers (increased E-cadherin, decreased N-cadherin, Vimentin, Slug) and apoptosis markers (promoted Caspase-3,8,9).
  • Intratumoral administration of Nanaomycin K significantly suppressed tumor growth in vivo without observed adverse effects.

Conclusions:

  • Nanaomycin K demonstrates potent anti-proliferative, anti-migratory, and pro-apoptotic effects in RCC.
  • Nanaomycin K effectively inhibits TGF-β-induced EMT in advanced RCC.
  • Nanaomycin K represents a promising therapeutic candidate for RCC treatment.
Keywords:
anti-cancer drugepithelial–mesenchymal transitionnanaomycin Krenal cell carcinoma

More Related Videos

Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

35.7K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K